Integra LifeSciences IART Specialty Surgery — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Integra LifeSciences's specialty surgery — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Integra LifeSciences's specialty surgery — R&D?
- Integra LifeSciences (IART) reported specialty surgery — R&D of $11.85M in Q1 2026.
- What does specialty surgery — R&D mean?
- This metric captures the investment allocated to innovation, clinical trials, and the development of new surgical technologies within the Specialty Surgery segment. It serves as a key indicator of the company's commitment to long-term product pipeline growth and future competitive advantage.